Healthcare data volume is expanding rapidly, but most sources remain siloed. This paper highlights the value of integrating disparate real-world data (RWD)—from claims, EMRs, registries, pharmacy, lab results, and patient-reported inputs—to generate richer insights across the product lifecycle. Regulators like Health Canada, FDA, and EMA now accept RWD in submissions, as seen with COVID-19 vaccines and rare disease approvals. Linking datasets enables robust evidence on safety, cost-effectiveness, and patient outcomes. IQVIA’s enriched study methods address fragmentation, overcoming privacy and interoperability barriers to support faster, more comprehensive decision-making.

Join for free to read